Mr Wayne Sheedy W.Sheedy@hull.ac.uk
Research Group Manager
IRONMAN: Effectiveness of Intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial
People Involved
Mike Lammiman
Andrew Clark
Project Description
A BHF funded study to compare the effect of additional intravenous iron IV therapy versus standard therapy for patients with chronic heart failure and left ventricular systolic dysfunction and iron deficiency.
Recruitment is 12 patients per year - we anticipate recruiting up to 28 patients over 2 years. Study duration is around 4.5 years.
HEY NHS Trust is a partner organisation for this study.
| Type of Project | Project |
|---|---|
| Project Acronym | IRONMAN |
| Status | Project Live |
| Funder(s) | British Heart Foundation |
| Value | £7,474.00 |
| Project Dates | May 5, 2017 - Aug 31, 2022 |
| Partner Organisations | Hull University Teaching Hospital NHS Trust |
You might also like
Perspective: A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction Jan 1, 2017 - Aug 31, 2022
A clinical trial of LCZ verses valsartan in heart failure patients with preserved ejection fraction. The study uses MRI and PET scans to identify amyloid deposits in the brain and any adverse effects of cognitive function of teh study drug, LCZ696.
AX-8 Clinical Research Collaboration Jun 1, 2016 - May 31, 2018
Primary:
Study the efficacy of compound AX-8 in suppressing cough and upper airway symptoms in subjects with cough hypersensitivity syndrome.
Secondary:
Study the safety of compound AX-8.
Development and application of a multi-scale computational model of sarcoidosis to predict therapeutic approaches for non-self-resolving disease Jun 30, 2017 - Aug 31, 2020
An in silico computational model of sarcoidosis
Galactic-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction Apr 1, 2017 - Jul 31, 2021
Acronym is derived from : Global approach to lowering adverse cardiac outcomes through improving contractility in heart failure.
A phase III randomised placebo controlled clinical trial sponsored by Amgen Inc of omecamtiv mercabil, a study dru...
Read More about Galactic-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.